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Ever since the outbreak of COVID-19 caused by Severe 
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in Wuhan, China, the world has witnessed the 
rapid spread of the pandemic across the world1. World 
Health Organization (WHO) reported approximately 
82,579,768 COVID-19 cases and 1,818,849 deaths as of 
January 2nd, 2021, with cases reported in more than 222 
countries/territories. This novel coronavirus outbreak 
has posed a severe burden to the global economic, 
medical, and public health infrastructure2.  
The COVID-19 is primarily a droplet-spread infection, 
and patients exhibit various symptoms of which fever, 
dry cough, and fatigue are predominant3. In some 
cases, the symptoms had rapidly developed to acute 
respiratory distress syndrome, metabolic acidosis, 
septic shock, coagulation dysfunction, eventually 
leading to multiple organ failure4-6. However, mild or 
asymptomatic COVID-19 patients can recover shortly 
after isolation and healthy lifestyle and food habits7. 
There is no particular treatment available for COVID-
19 infection except for comprehensive support by the 
combination of broad-spectrum antibiotics, antiviral 
and anti-malarial drugs, corticosteroids, and 
convalescent plasma therapy8. Numerous clinical 
trials are in progress, including identifying vaccines 
against SARS-CoV-2. Researchers and health care 
professionals are in desperate search of an effective 
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The Indian Traditional Medicines System has long used Siddha 
polyherbal formulations for different viral diseases. The ingredients of 
these formulas have been proven to be antiviral. The study focuses on 
in silico computational evaluation of phytoconstituents of the official 
Siddha formulation Kabasura, Thonthasura, and Vishasura Kudineer, 
which were widely used in treating viral fever and respiratory 
infections and may influence the current SARS-CoV-2 coronary virus 
pandemic. Maestro interface (Schrödinger Suite, LLC, NY) was used 
for molecular docking studies against MPro (PDB ID 5R82, 6Y2F, and 
6LU7), Nsp15 endoribonuclease (6W01), RNA-dependent RNA 
polymerase (6M71), and spike protein (6VW1) of SARS-CoV-2. In 
addition, pharmacokinetics (ADME) and safety profile prediction 
studies were performed to identify the best drug candidates using 
Qikpro and Toxicity Estimation Software Tool (T.E.S.T). A total of 36 
compounds were screened, of which nine displayed strong binding 
affinity and drug-likeness. Luteolin and chrysoeriol produced 
stronger results. These nine compounds were free of oral toxicity as 
evaluated by the Toxicity estimation software. Based on further in 
vitro, in vivo, and clinical effectiveness trials, these compounds may be 
used for the prevention or treatment as per the Indian system of 
traditional medicines. 
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cure for this pandemic. In the current scenario where 
the conventional drugs do not prove to be much 
efficacious, exploring the traditional system of 
medicine could be a feasible and hopeful strategy9. 
Traditional, complementary, and alternative medicine 
has a long history of providing primary beneficial 
health care to the population10.  
India has an unmatched alternative system of 
medicine in the form of Ayurveda, Yoga, and 
Naturopathy, Unani, Siddha, Homeopathy, which is 
now jointly referred to as Ayush, recognized by the 
Government of India11. Siddha Medicine is one of 
India’s oldest (5000 years old) and well-documented 
medical systems and is practiced mainly in South 
India, especially in Tamil Nadu and Sri Lanka, 
Malaysia, Singapore, and Mauritius, where Tamils 
live12. In the current pandemic situation, many 
strategies would be highly critical to combat the rapid 
virus spread and treat the infection. Ministry of Ayush, 
Government of India has issued an “Advisory on 
Coronavirus” to manage this outbreak and broadly 
comprises of preventive and prophylactic symptom 
management of COVID-19 like illnesses and also 
insights to interventions based on Ayush systems of 
medicine through the evidence for immunity boosting 
as well as help in improving the respiratory 
symptoms13.  
Drug discovery and development involve a long time, 
a vast number of individuals, high prices. In silico 
screening approaches allow researchers to explore 
new and potentially active lead compounds in less 
time, expense, and humans14. Siddha polyherbal 
formulations are potent against several causative 
agents such as influenza, chikungunya, dengue, 
tuberculosis, and others15-17. Siddha medicines have 
been used successfully by Siddha practitioners and 
ordinary citizens for the treatment of many diseases 
for several years, such as Kabasura Kudineer during 
influenza outbreaks, Nilavembu Kashayam for 
dengue fever. Kabasura kudineer, Thonthasura 
kudineer, and Vishasura kudineer are polyherbal 
formulations that have long been used in Siddha 
medication for different health problems, including 
currently being developed for COVID-19 therapy18-19. 
These polyherbal formulas are made up of different 
medicinal plants. 
This study aims to evaluate the activity of 
phytoconstituents in Siddha polyherbal formulations 
against various potential SARS-CoV-2 targets using in 
silico methods. Thirty-six phytoconstituents were 
selected from these medicinal plants and docked 
against all potential SARS-CoV-2 targets, including 
MPro, Nsp15 endoribonuclease, RNA-dependent RNA 
polymerase (RdRp), and spike protein, utilizing 
Maestro 11.8 (Schrodinger 2018-4 package). 
 
METHOD 
Hardware and Software 
Software used includes Maestro 11.8 from 
Schrödinger, Inc 
(https://www.schrodinger.com/products/maestro) 
and Toxicity Estimation Software Tool (T.E.S.T.) 4.2.1 




Hygrophila auriculata, Piper longum, Syzygium 
aromaticum, Tragia involucrata, Clerodendrum serratum, 
Anacyclus pyrethrum, Terminalia chebula, Adhatoda 
vasica, Coleus amboinicus, Saussurea lappa, Tinospora 
cordifolia, Andrographis paniculata, Sida acuta, Cyperus 
rotundus, and Zingiber officinale were the 15 ingredients 
of Kabasura Kudineer20,21. The Thonthasura Kudineer 
contains ten ingredients, including Z. officinale, A. 
vasica, A. paniculata, T. cordifolia, Elettaria cardamomum, 
Solanum xanthocarpum, Trichosanthes cucumerina, 
Tephrosia purpurea, Mollugo cerviana, and Vitis vinifera22. 
While the Vishasura Kudineer consists of nine 
ingredients, including Azadirachta indica, Z. officinale, 
Hemidesmus indicus, Indigofera tinctoria, Aristolochia 
bracteolata, E. cardamomum, Vetiveria zizanioides, 
Santalum album, and Glycyrrhiza glabra23. 
The major active phytoconstituents present in those 
plants were selected. The selected 36 
phytoconstituents including β-sesquiphellandrene 
(PubChem ID 11106487), β-bisabolene (10104370), 
geranial/citral (638011), piperine (638024), 
piperlonguminine (5320621), eugenol (3314), β-
caryophyllene (5281515), stigmasterol (5280794), 
squalene (638072), γ-sitosterol/clionasterol (457801), 
andrograpanin (11666871), moslosooflavone/5-
hydroxy-7,8-dimethoxyflavone (188316), lupeol 
(259846), betulin (72326), chebulagic acid (442674), 
gallic acid (370), vasicinone (10242), carvacrol (10364), 
cirsimaritin (188323), chrysoeriol (5280666), luteolin 
(5280445), costunolide (5281437), elemol (92138), 
tinosponone (15215479), bharangin (194464), 
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scutellarein (5281697), magnoflorine (73337), 
cycleanine (121313), cyperene (99856), β-selinene 
(442393), zingiberene (92776), vasicine (442929), 
cucurbitacin B (5281316), andrographolide (5318517), 
apigenin (5280443), pyrethrin I (5281045), and the 
reference drugs (chloroquine, hydroxychloroquine, 
ivermectin, lopinavir, remdesivir, and ritonavir) were 
downloaded from the PubChem database 
(https://pubchem.ncbi.nlm.nih.gov/). 
Receptors 
All potential SARS-CoV-2 targets, including MPro, 
Nsp15 endoribonuclease, RdRp, and spike protein, 
have been selected to evaluate the optimum ligand. 
The 3D structure of selected proteins has been 
downloaded from Protein Data Bank 
(https://www.rcsb.org). The PDB ID of the selected 
proteins was MPro (5R82, 6Y2F, 6LU7), Nsp15 
endoribonuclease (6W01), RdRp (6M71), and spike 
protein (6VW1)24-29. 
Docking protocol 
Preparation of ligands 
The ligand minimization was carried out by the 
LigPrep module in Maestro 11.8. The 3D ligand 
structure was generated, and hydrogen atoms were 
introduced. Salt reduction and ionization (pH 7.0±2.0) 
were conducted, and the minimization was performed 
utilizing the OPLS-2005 force field30,31. 
Preparation of protein 
Protein Preparation Wizard was used to prepare 
protein structures. Bond orders were assigned, and 
hydrogen atoms were inserted. Within 3 Å of the het 
groups, the water molecules were removed, and the 
missing side chains were filled with prime. As a result, 
hydrogen bonds (H-bond) were optimized and 
reduced using the OPLS 2005 force field. The co-
crystallized ligand binding sites have been identified 
after elimination. The receptor grid was then created 
using the "Glide's Receptor Grid Generation" module 
with a 20 Å radius30,31. 
Molecular docking and free energy calculation 
The molecular docking between receptor binding sites 
and ligands was conducted using the Glide Module of 
Maestro 11.8, and the lowest binding pose of each 
ligand was maintained. Glide docking scores were 
performed in three high-throughput virtual screening 
(HTVS), standard precision (SP), and extra precision 
(XP) modes. Firstly, docking was performed with 
reference molecules of respective proteins to validate 
the docking protocol. We used the XP mode for 
docking. After XP mode docking, compounds were 
sent to Prime MMGBSA from Maestro 11.8 for free 
energy calculations. 
ADME and toxicity analysis 
Out of the 36 compounds, ten compounds were 
chosen based on the docking performance. The chosen 
compounds were used in the ADME study using the 
QikProp module from Maestro 11.8, and the following 
parameters were determined.  
1. The molecular weight of the molecule. 
2. Predicted octanol/water partition coefficient. 
3. Predicted brain/blood partition coefficient. 
4. Percent human-oral absorption 
5. Lipinski’s rule of five.  
a. mol_MW <500 
b. QPlogPo/w <5 
c. donorHB ≤5 
d. accptHB ≤10 
6. Jorgensen’s rule of three 
a. QPlogS >-5.7 
b. QP PCaco >22 nm/s 
c. # Primary Metabolites <7 
Toxicity was measured using T.E.S.T. 4.2.1. Oral rats 
LD50, developmental toxicity, and Ames mutagenicity 
were conducted using four methods: Consensus 
system, Hierarchical clustering method, FDA method, 
and Nearest neighbor method32. 
1. Hierarchical method [HM]: Using the weighted 
average of estimates from several separate models, 
the toxicity of a specified question compound was 
determined. Using the Ward approach to fragment 
the training set into a sequence of structurally 
linked clusters, the separate models were obtained. 
A genetic algorithm-based approach was used to 
create models for each cluster. Models were 
created before runtime. 
2. FDA Method [FM]: For and test product, the 
prediction was produced using a new model 
appropriate for chemicals closest to the test 
compound. Each model was generated at runtime. 
3. Nearest neighbor method [NM]: The predicted 
toxicity was calculated by taking an average of the 
three chemicals most comparable to the research 
chemicals in the training kit. 
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4. Consensus Method [CM]: The predicted toxicity 
was calculated by taking an average of the 
predicted toxicity from the QSAR as mentioned 
earlier methods (provided the predictions were 
within the respective applicability domains). 
 
RESULTS AND DISCUSSION 
Molecular docking and free energy calculation 
Compounds with a docking score of less than -6.0 
were deemed possible candidates against SARS-CoV-
2, as represented in Table I for a comparative study. 
Out of 36 molecules, luteolin, chrysoeriol, and 
cucurbitacin B have been associated with more than 
two receptor structures. Luteolin displays a docking 
score less than -6 with MPro, Nsp15 endoribonuclease, 
and RdRp, as seen in Figure 1. 
Table I. Comparative docking analysis of ligands against 
MPro, Nsp15 endoribonuclease, RdRp, and spike 
protein 
Compounds 
Receptors (PDB ID) 
5R82 6Y2F 6LU7 6W01 6M71 6VW1 
Remdesivir -5.478 -5.306 -7.189 -7.829 -8.643 -7.206 
Hydroxychloroquine -5.395 -2.741 -4.438 -4.814 -4.177 -8.748 
Chloroquine -4.203 -1.587 -3.98 -5.896 -2.191 N/A* 
Lopinavir -5.373 -3.5 -4.535 -5.953 -7.797 -6.702 
Ritonavir -3.927 -5.233 -6.79 -5.848 -1.198 -6.493 
Ivermectin -3.037 -3.427 -4.44 -4.187 -3.558 N/A 
Luteolin -7.408 -6.036 -7.47 -7.314 -6.304 N/A 
Scutellarein -6.807 -6.081 -7.587 -7.191 N/A N/A 
Chrysoeriol -6.473 -6.394 -7.342 -6.43 -6.174 N/A 
Cucurbitacin B -6.267 N/A -6.946 -7.021 -6.488 N/A 
Apigenin -6.065 N/A -6.22 -6.41 N/A N/A 
Andrographolide -6.042 N/A N/A N/A N/A N/A 
Cirsimaritin -6.031 N/A -6.743 -6.461 N/A N/A 
Moslosooflavone -6.003 N/A -6.973 N/A N/A N/A 
Gallic acid N/A N/A N/A -6.379 N/A N/A 
Pyrethrin N/A N/A N/A N/A -6.704 N/A 
Cycleanine N/A N/A N/A N/A N/A -6.907 
*N/A: Not available 
 
 
Figure 1. Binding-interaction analysis of luteolin with (a) MPro, 
with (b) RdRp, and with (c) Nsp15 endoribonuclease. 
 
Chrysoeriol also displays a docking score less than -6.0 
with MPro, Nsp15 endoribonuclease, and RdRp, as 
seen in Figure 2. The associations of luteolin and 
chrysoeriol with various SARS-CoV-2 target forms 
were comparatively analyzed, in which H-bond and 
hydrophobic pockets were presented in Tables II and 
III. Luteolin shows hydrogen bonding with nearly 
four amino acids of most of the targets. This finding 
shows its high binding potency towards the SARS-
CoV-2.  
 
Figure 2. Binding-interaction analysis of chrysoeriol with (a) 
MPro, with (b) RdRp, and with (c) Nsp15 endoribonuclease. 
 
Table II. Binding interactions of luteolin with the active sites 




H-Bond Hydrophobic pocket 
MPro 
 
5R82 GLY 143, 
THR 26, 
THR 25 
CYS 145, MET 165, 
MET 49, LEU 27 
6LU7 THR 26 LEU 27, CYS 145, 
CYS 44, MET 49, PRO 
52, TYR 54, MET 165 




LEU 27, VAL 42, CYS 
44, TYR 54, MET 49, 
PHE 140, LEU 141, 
LYS 145, MET 165 
RdRp 
 




PHE 396, CYS 395, 
VAL 315, PRO 627, 









PRO 271, LEU 252, 
VAL 295, ILE 296, 
VAL 276, TYR 279 
 
Table III. Binding interactions of chrysoeriol with the active 




H-Bond Hydrophobic pocket 
MPro 5R82 GLN 189, 
GLY 143, 
THR 26 
CYS 145, LEU 27, 
MET 49, MET 165 
6LU7 THR 26 CYS 44, PRO 52, MET 
49, TYR 54, MET 165, 
CYS 145, LEU 27 
6Y2F ASP 187, 
GLU 166, 
LEU 141 
CYS 44 , LEU 141, 
CYS 145, MET 165, 
TYR 54, MET 49 
RdRp 
 
6M71 VAL 315, 
GLU 350 
VAL 315, PRO 461, 
LEU 460, PHE 396, 
CYS 395, TYR 456, 




6W01 LYS 71, 
SER 275, 
LYS 90 
TYR 279, MET 272, 
PRO 271, LEU 252 
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In the molecular docking of phytoconstituents with 
MPro (5R82), luteolin had a higher affinity with a 
docking score of -7.408, followed by scutellarein and 
chrysoeriol with docking scores of -6.807 and -6.473, 
respectively. These phytoconstituents had a higher 
affinity to MPro (5R82) than remdesivir, displaying a 
docking score of -5.478. Chrysoeriol had a higher 
affinity with a docking score of -6.394, followed by 
scutellarein and luteolin with docking scores of -6.081 
and -6.036, respectively with the target MPro (6Y2F). 
These phytoconstituents had a higher affinity to MPro 
(6Y2F) than remdesivir, with a docking score of -5.306. 
Scutellarein had a greater affinity with a docking score 
of -7.587, followed by luteolin and chrysoeriol with -
7.470 and -7.342, respectively, for molecular docking of 
phytoconstituents with MPro (6LU7). These 
phytoconstituents had a higher affinity than 
remdesivir, which had a docking score of -7.189. 
Remdesivir shows greater affinity with a docking 
score of -7.829, followed by scutellarein and 
cucurbitacin B with a score of -7.314 and -7.191, 
respectively, in the docking analysis with Nsp15 
endoribonuclease (6W01). With RdRp (6M71), 
remdesivir had a higher affinity with a docking score 
of -8.643, followed by pyrethrin and cucurbitacin B 
with docking scores -6.704 and -6.488, respectively. 
Hydroxychloroquine had a higher affinity with a 
docking score of -8.748, followed by remdesivir and 
cycleanine, which had a docking score of -7.206 and -
6.907, respectively, with the target spike protein 
(6VW1). Most phytoconstituents exhibited similar 
reference drugs in binding energies and binding 
pockets, except gallic acid, pyrethrin, chebulagic acid, 
and cycleanine. 
Chrysoeriol shows less hydrogen bonding than the 
luteolin but better than other phytoconstituents. The 
hydrogen bonding of both luteolin and chrysoeriol 
could be increased by substitute better chemical 
groups. The prime MM-GBSA was generally accepted 
for the re-scoring of docked complexes. Both of the 
chosen complexes were subjected to prime MM-GBSA 
measurements after XP Docking33. MM-GBSA DG-
bind scores for all chosen compounds were displayed 
in Table IV. The negative DG-bind values indicate 
that the selected compounds associate favorably with 
the receptor. Ligand binding energies for both 
substances vary from -40.0 to -100.0 kcal/mol. The 
binding energies of several of the substances were 
relatively close to those of the reference drug binding 
energy. These findings indicate that the selected 
compounds would inhibit SARS-CoV-2. 
Table IV. MM-GBSA DG-bind values of selected compounds 
Compounds 
Receptors (PDB ID) (kcal/mol) 
5R82 6Y2F 6LU7 6W01 6M71 6VW1 
Remdesivir -63.6 -74.01 -79.74 -61.48 -73.53 -47.55 
Hydroxychloroquine -77.77 -94.09 -64.02 -46.21 N/A* -64.72 
Chloroquine -62.03 -87.32 -78.62 -36.65 N/A -66.13 
Lopinavir -59.92 -52.27 -48.39 -47.87 -93.51 -70.62 
Ritonavir -93.22 -88.95 -96.23 -69.29 N/A -31.95 
Ivermectin -62.33 -59.89 -55.15 -66.39 N/A -54.7 
Luteolin -45.23 -26.87 -54.84 -41.3 -48.75 N/A 
Scutellarein -43.21 -41.37 -50.83 -44.21 N/A N/A 
Chrysoeriol -56.63 -23.2 -56.63 -39.5 -54.83 N/A 
Cucurbitacin B -82.11 N/A -63.88 -58.96 -79.78 N/A 
Apigenin -45.79 N/A -52.44 -43.85 N/A N/A 
Andrographolide -69.79 N/A -51.5 N/A N/A N/A 
Cirsimaritin -53.92 N/A -55.73 -50.21 N/A N/A 
Moslosooflavone -51.89 N/A -56.77 N/A N/A N/A 
Gallic acid N/A N/A N/A -18.15 N/A N/A 
Pyrethrin N/A N/A N/A N/A -79.94 N/A 
Cycleanine -63.6 -74.01 -79.74 -61.48 -73.53 -47.55 
*N/A: Not available 
 
ADME analysis 
The absorption, distribution, metabolism, and 
elimination of substances play an essential role in the 
drug development phase. In silico ADME analysis 
would save thousands of dollars spent in the drug 
development phase by producing fewer new 
compounds34. The ADME parameters, such as mol 
MW, QPlogPo/w, QPlogBB, percent human oral 
absorption, Rule of Five, and Rule of Three using 
QikProp showed a better score for the docked 
compounds35. Both of the chosen nine compounds 
have enhanced ADME properties and drug-likeness 
according to the spectrum as shown in Table V. All of 
the nine phytoconstituents have enhanced ADME 
properties. Cucurbitacin B violates a rule of 1 of 5, 
which was appropriate. Gallic acid and pyrethrin were 
in breach of a law of three that was fitting. Luteolin and 
chrysoeriol display improved drug-likeness and high 
binding capacity, all of which were essential to the 
drug candidate. 





































































Andrographolide 350.454 -1.222 1.437 79.068 0 0 
Apigenin 270.241 -1.411 1.624 73.955 0 0 
Chrysoeriol 300.267 -1.409 1.81 76.672 0 0 
Cucurbitacin B 558.711 -1.964 2.92 67.293 1 0 
Gallic acid 170.121 -1.659 -0.585 41.441 0 1 
Luteolin 286.24 -1.91 0.941 62.05 0 0 
Pyrethrin 372.46 -1.157 4.385 100 0 1 
Scutellarein 286.24 -1.819 1.001 63.924 0 0 
Moslosooflavone 298.295 -0.43 3.165 100 0 0 
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In silico toxicity study 
The oral rat LD50 
The endpoint of the oral rat LD50 was the amount of 
the chemical (chemical mass per rat body weight) that 
destroys half of the rats when administered orally36. 
The oral rat LD50 was conducted in four methods for 
all of the chosen compounds, and the findings were 
comparatively evaluated in Table VI. All substances 
have been shown to have an acceptable toxicity limit 
for drug production and preclinical and clinical 
assessment. 
Developmental toxicity 
Developmental toxicity includes embryonic and fetal 
mortality, miscarriage, and other abnormal 
developmental symptoms such as liver toxicity, 
lowered body weight, growth, developmental 
retardation, and physical abnormalities (teratogenic 
effects)37. Developmental toxicity was performed in 
four approaches with all of the chosen compounds, 
and the findings were comparatively analyzed in 
Table VI. A predicted value greater than 0.5 indicates 
toxicity. Except gallic acid, all other compounds show 
developmental toxicity. 
Ames mutagenicity 
In Ames assay, frame-shift mutations or base-pair 
substitutions could be identified by exposure of 
histidine-dependent strains of Salmonella typhimurium 
to the test compound. When these strains were 
exposed to a mutagen, reversing mutations that 
restore the functional capacity of the bacteria to 
synthesize histidine would cause the bacterial colony 
to develop on a medium histidine deficiency 
(revertant)38. 
A compound was labeled Ames positive if it 
significantly induces the development of the reverting 
colony in at least one of the five strains. If a compound 
was positive for the Ames test, it could be a possible 
mutagen39. Ames mutagenicity was conducted in four 
methods for all of the chosen compounds, and the 
findings were comparatively analyzed in Table VI. A 
predicted value greater than 0.5 indicates 
mutagenicity. All the nine phytoconstituents except 
pyrethrin were not mutagens based on the results on 
the Ames mutagenicity as predicted by T.E.S.T 
software. 
 
Table VI. Predicted value for oral rat LD50 – Log10 (mol/kg), 

























































































































































































































































































































































































































































HM: Hierarchical method; FM: FDA method; NM: Nearest neighbor 
method; CM: Consensus method; N/A: Not available 
 
Our current research has chosen three Official Siddha 
Formulation Kabasura, Thonthasura, and Vishasura 
Kudineer to test its potential against SARS-CoV-2 
targets. Siddha medicine is one of the oldest Indian 
systems of medicine. The methods of Siddha emerged 
in India, and it was most commonly practiced in India, 
especially in southern regions. Siddha medicinal 
plants were a promising area for the treatment of a 
wide variety of diseases. Siddha medicinal plants 
might also be considered a new choice for their role in 
overcoming viral transmission40,41. 
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Mekala and Krishnamurthy42 performed the 
phytochemical screening and pharmacological update 
on Kabasura Kudineer Choornam and Nilavembu 
Kudineer Choornam. Kabasura Kudineer was found 
to have alkaloids, carbohydrates, glycosides, heart-
glycosides, flavonoids, phenols, saponins, and 
hydrolyzable present in Kabasura Kudineer 
Choornam. In addition to the broad range of other 
pharmacological operations, the ingredients in 
Kabasura Kudineer show that most of the components 
were antipyretic, anti-inflammatory, antimicrobial, 
and immunostimulant43. Therefore, it was 
scientifically rational to use it in respiratory viral 
infection. 
The molecular docking study of Thonthasura 
Kudineer ingredients demonstrated affinity with the 
Coronavirus Spike (S) glycoprotein, carried out by 
Kumar et al22. Vishasura Kudineer was a polyherbal 
formulation from the Siddha literature 'Kaaviya Sura 
Nool'. Vishasura Kudineer was traditionally used for 
symptoms associated with viral fever. Its portion 
demonstrates antiviral activity against a wide variety 
of viruses. It might also be antipyretic, antiasthmatic, 
anti-inflammatory, antioxidant, hepatoprotective, and 
immunostimulant18. 
Various research studies have been performed on 
different formulations of Siddha and its 
phytoconstituents against selective targets for SARS-
CoV-219,22,44. The main protease (MPro, 3CLPro, Nsp5) 
proteolytically cleaves the overlapping pp1a and 
pp1ab polyproteins to functional proteins, crucial in 
viral replication. In the viral replication cycle, the MPro 
acts as the primary enzyme. Its inhibition could thus 
interfere with the production of infectious virus 
particles and reduce disease symptoms45. 
The SARS-CoV-2 spike protein mediates the binding 
of the virus to its receptor angiotensin-converting 
enzyme 2 (ACE2) and facilitates the integration of viral 
and host cell membranes and the entrance of the virus 
into the host cell. Thus, the Spike protein was vital in 
neutralizing and T-cell reactions and maintaining 
immunity during SARS-CoV-2 infection. Given the 
essential role of the S-protein in viral infection and 
adaptive immunity, most methods and therapies were 
based on the S-protein46. RNA-dependent RNA 
Polymerase was an enzyme that replicates RNA from 
an RNA template. RNA-dependent RNA Polymerase 
was one of the Nsp (Nsp12) that plays a key role in the 
coronavirus life cycle47. 
Nsp15 was responsible for protein interaction with the 
innate immune response, although other studies 
suggest that the mechanism was independent of 
endonuclease activity. In order to conceal it from the 
host's immune system, there were also reports that 
Nsp15 degrades viral RNA48. Nevertheless, in 
coronavirus biology, Nsp15 was important. The active 
site, located in a shallow groove between the two β‐
sheets, carries six key residues conserved among 
SARS‐CoV‐2, SARS‐CoV, and MERS‐CoV proteins: 
His235, His250, Lys290, Thr341, Tyr343, and Ser29427. 
 
CONCLUSION 
The present research was planned to classify potential 
drug candidates exhibiting potential binding affinity 
to all possible SARS-CoV-2 targets (MPro, Nsp15 
endoribonuclease, RdRp, and spike protein). Based on 
the findings obtained from molecular docking, free 
energy measurement, ADME analysis, as well as 
toxicity analysis, luteolin and chrysoeriol exhibit 
stronger docking score, binding energy, ADME 
properties, and lower toxicity than all other 
compounds. 
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